 Morpholines
"Morpholines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D009025
|
| MeSH Number(s) |
D03.383.533.640
|
| Concept/Terms |
Morpholines- Morpholines
- Tetrahydro-1,4-Oxazines
- Tetrahydro 1,4 Oxazines
|
Below are MeSH descriptors whose meaning is more general than "Morpholines".
Below are MeSH descriptors whose meaning is more specific than "Morpholines".
This graph shows the total number of publications written about "Morpholines" by people in this website by year, and whether "Morpholines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 2000 | 0 | 2 | 2 | | 2002 | 0 | 4 | 4 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 2 | 2 | | 2006 | 2 | 2 | 4 | | 2008 | 0 | 3 | 3 | | 2009 | 3 | 1 | 4 | | 2010 | 3 | 1 | 4 | | 2011 | 5 | 1 | 6 | | 2012 | 3 | 3 | 6 | | 2013 | 8 | 2 | 10 | | 2014 | 9 | 3 | 12 | | 2015 | 1 | 3 | 4 | | 2016 | 0 | 2 | 2 | | 2017 | 3 | 2 | 5 | | 2018 | 2 | 0 | 2 | | 2019 | 0 | 1 | 1 | | 2020 | 2 | 3 | 5 | | 2021 | 0 | 3 | 3 | | 2022 | 0 | 2 | 2 | | 2024 | 2 | 3 | 5 | | 2025 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Morpholines" by people in Profiles.
-
Shulman DS, Vo KT, Balis FM, Lindsay H, Bagatell R, Place AE, Chi SN, Shusterman S, Ezrre S, Czaplinski J, Bhushan K, Kao PC, London WB, DuBois SG. A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors. Cancer Med. 2025 Dec; 14(23):e71417.
-
Pasco R, Hayden FG, Meyers LA. Modeling Influenza Antiviral Strategies: Reducing Burden and Preventing Resistance. J Infect Dis. 2025 Oct 17; 232(Supplement_3):S299-S308.
-
Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, Patel RP, Tan M, Padmanabhan AA, Lemoine J, Fardella E, Zhang Y, Pajarillo R, Chen L, Ugwuanyi O, Markowitz K, Delman D, Angelos MG, Shestova O, Isshiki Y, Blanchard T, Béguelin W, Melnick AM, Linette GP, Beatty GL, Carreno BM, Cohen IJ, Paruzzo L, Schuster SJ, Ruella M. EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell. 2025 Mar 10; 43(3):537-551.e7.
-
Collins SP, Shotwell MS, Strich JR, Gibbs KW, de Wit M, Files DC, Harkins M, Hudock K, Merck LH, Moskowitz A, Apodaca KD, Barksdale A, Safdar B, Javaheri A, Sturek JM, Schrager H, Iovine NM, Tiffany B, Douglas I, Levitt J, Ginde AA, Hager DN, Shapiro N, Duggal A, Khan A, Lanspa M, Chen P, Gentile N, Harris E, Gong M, Sellers S, Goodwin AJ, Tidswell MA, Filbin M, Desai N, Gutiérrez F, Estrada V, Burgos J, Boyles T, Paño-Pardo JR, Hussen N, Rosenberg Y, Troendle J, Bernard GR, Bistran-Hall AJ, Walsh K, Casey JD, DeClercq J, Joly MM, Pulley J, Rice TW, Schildcrout JS, Wang L, Semler MW, Self WH. Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial. JAMA Netw Open. 2024 12 02; 7(12):e2448215.
-
Nielsen AJ, Albert GK, Sanchez A, Chen J, Liu J, Davalos AS, Geng D, Bradeen X, Hintzsche JD, Robinson W, McCarter M, Amato C, Tobin R, Couts K, Wilky BA, Davila E. DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors. J Clin Invest. 2024 Oct 22; 134(24).
-
Leonard AC, Friedman AJ, Chayer R, Petersen BM, Woojuh J, Xing Z, Cutler SR, Kaar JL, Shirts MR, Whitehead TA. Rationalizing Diverse Binding Mechanisms to the Same Protein Fold: Insights for Ligand Recognition and Biosensor Design. ACS Chem Biol. 2024 08 16; 19(8):1757-1772.
-
Harrington J, Hellkamp AS, Mahaffey KW, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Fox KAA, Singer DE, Goodman SG, Patel MR, Piccini JP. Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis. J Am Heart Assoc. 2024 Jun 04; 13(11):e028951.
-
Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, Specht JM, Dees EC, Kabos P, Suzuki S, Mutka SC, Sullivan BF, Gorbatchevsky I, Wesolowski R. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol. 2024 04; 25(4):474-487.
-
Priestley ES, Banville J, Deon D, Dubé L, Gagnon M, Guy J, Lapointe P, Lavallée JF, Martel A, Plamondon S, Rémillard R, Ruediger E, Tremblay F, Posy SL, Guarino VR, Richter JM, Li J, Gupta A, Vetrichelvan M, Balapragalathan TJ, Mathur A, Hua J, Callejo M, Guay J, Sum CS, Cvijic ME, Watson C, Wong P, Yang J, Bouvier M, Gordon DA, Wexler RR, Marinier A. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4. J Med Chem. 2022 07 14; 65(13):8843-8854.
-
Calcaterra SL, Butler M, Olson K, Blum J. The Impact of a PDMP-EHR Data Integration Combined With Clinical Decision Support on Opioid and Benzodiazepine Prescribing Across Clinicians in a Metropolitan Area. J Addict Med. 2022 May-Jun 01; 16(3):324-332.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|